Health ❯Healthcare
Mergers and Acquisitions Investments Market Analysis Biotechnology Gene Editing Technologies Market Reactions Investment Strategies Market Risks Drug Development Valuation
The $1.3 billion purchase marks a major step in Lilly’s expansion into PCSK9-targeting therapies with closing slated for Q3 2025.
